Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by perfectlysizzlingpizza-blog and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
1 hour ago
Number of Posts By Type
Text
17
Last Seen Tumblr Blogs
Fun Fact
Tumblr Inc. is using 66 technologies for its website.
Text
Hypothyroidism Disorder Treatment Market Detailed Study Analysis with Forecast by 2025
Hypothyroidism disorder, also known as underactive thyroid disease, is a common disorder caused by a lack of or inefficient secretion of the thyroid hormone by the thyroid gland. It results in inadequate levels of the hormone in the body. The thyroid gland is located at the front lower part of the neck. The thyroid hormone secreted by the gland affects every part of the body including muscles, skin, heart, and brain. As per a report published by the American Association of Clinical Endocrinologists (AACE), out of 27 million people suffering from thyroid disorders, most suffer from hypothyroidism, while autoimmune thyroiditis is the most common cause.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/hypothyroidism-disorder-treatment-market.html
Other causes that might lead to hypothyroidism disorder include too much or too little iodine intake, surgery of thyroid gland, damage to the pituitary gland, rare disorders that infiltrate the thyroid, radiation treatment, congenital hypothyroidism, and thyroiditis medicines. In early stages, hypothyroidism disorder may reflect few symptoms. However, with time the symptoms may increase as thyroid hormone secretion decreases significantly and the body’s metabolism slows down. Common symptoms of hypothyroidism disorder include difficulty with learning; dry, itchy skin; dry, brittle hair and nails; constipation; drowsiness; heavy and/or irregular menstrual flow; increased sensitivity to many medications; increased frequency of miscarriages; forgetfulness; pervasive fatigue; puffy face; sore muscles; weight gain; and fluid retention.
There is no cure for hypothyroidism disorder, but it can be easily controlled by hormone replacement therapy, which brings the thyroid hormone level back to normal. The therapy has been used for more than a century for treating hypothyroidism disorder. The first synthetic molecule used for treatment of hypothyroidism disorder was L-Thyroxine (T4). Before the discovery of this molecule, desiccated thyroid extracted from animals was the only available treatment for hypothyroidism disorder. Levothyroxine sodium tablets were first approved as a novel drug in 1997 by the U.S. FDA, but was an unapproved marketed drug till August 2000. Synthetic T4 hormone contains thyroxine that is produced by a normal thyroid hormone. Currently, six brands of synthetic T4 have been approved by the FDA for standard treatment of hypothyroidism disorder including, Levo-T, Levothyroxine Sodium, Levoxyl, Novothyrox, Synthroid, and Unithroid.Moreover, use of T3 drug Cytomel has proved to be beneficial for patients who face difficulty with use of synthetic T4 pills. All hypothyroid patients are generally treated as outpatients, except for those suffering from myxedema.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39311
Lack of awareness or inaccurate diagnosis leads to failure of timely treatment and management of hypothyroidism, which is a major restraint for the hypothyroidism disorder treatment market. For instance, according to the National Health and Nutrition Examination Survey (NHANES ) in2016, out of 17,353 patients, about 9.2% had clinically significant thyroid disorder based on chemical test criteria. According to the American Thyroid Association annual report in 2015, it was estimated that approximately 20 million Americans had a thyroid disorder, and about 60% of them were unaware of their clinical condition due to the non-specific nature of symptoms. Patients also had a tendency to downplay the symptoms. Pharmaceutical companies, however, are dedicated to research and development of novel diagnosis and drugs that prove beneficial for hypothyroid disorder management. Thus, approval of many novel drugs for hypothyroidism disorder in the near future is expected to propel the hypothyroidism disorder treatment market during the forecast period.
The hypothyroidism disorder treatment market can be segmented based on drug type, distribution channel, and region. Based on drug type, the hypothyroidism disorder treatment market can be categorized into synthetic levothyroxine (L-T4) and L-triiodothyronine (T-3). In terms of distribution channel, the hypothyroidism disorder treatment market can be split into drug stores, hospital pharmacy, online pharmacy, retail pharmacy, and others.. Based on region, the hypothyroidism disorder treatment market can be classified into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America. Key players in the hypothyroidism disorder treatment market are Abbott Laboratories (AbbVie), Alara Pharm, Manus Aktteva Biopharma LLP, MOVA Pharmaceutical, Pfizer Inc, Merck KGaA, and other prominent players.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39311
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Forecast and Analysis on Hyperhidrosis Treatment Market for Period 2017 - 2025
Hyperhidrosis, a disorder characterized by excessive sweating, can be focal or generalized. The severity of hyperhidrosis can vary from slight wetness to severe wet and can cause significant damage to the quality of life, which includes limitations in social and work relationships, leisure, and physical activities. It can even impact mental and emotional health. Hyperhidrosis can occur due to medical conditions such as diabetes, injury, such as head trauma caused by an accident, menopause, obesity, and overactive thyroid (hyperthyroidism). It affects multiple body parts, most frequently the armpits, palms, face or soles. Nearly 3% of the population, mostly individuals aged between 25 and 64 years, suffer from hyperhidrosis. Hyperhidrosis brings a significant social and psychological burden, as it hampers daily activities. However, individuals suffering from this disorder rarely seek medical help, as several patients are unaware that they are suffering from a treatable medical disorder. Primary recognition and managing of hyperhidrosis can significantly recover a patient’s quality of life. There are several systemic, topical, surgical and nonsurgical treatments available with effectiveness rates ranging between 90% and 95%.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/hyperhidrosis-treatment-market.html
The global market of hyperhidrosis can be segmented based on type, treatment, end user, and geography. Based on type, the hyperhidrosis market can be classified into generalized and focal. Generalized hyperhidrosis includes the complete body and is generally a part of the primary condition, most often an endocrine, infectious, or neurologic disorder. Focal hyperhidrosis is idiopathic, arising in healthy people. Based on treatment, the hyperhidrosis market can be segregated into topical treatments, Iontophoresis, Botulinum toxin A, surgical treatments, and systemic treatments. Topical treatment includes aluminum salts, which is the most common over-the-counter ingredient in antiperspirants that are utilized to treat focal hyperhidrosis. Moreover, aldehyde agents such as glutaraldehyde and formaldehyde are also employed to treat hyperhidrosis as topical treatments. Iontophoresis is the diffusion of ions into the skin by means of an electrical current. Botulinum toxin A is used to treat hyperhidrosis, which is a form of neurotoxin produced by the anaerobic bacterium Clostridium botulinum. Surgical treatments comprise endoscopic thoracic sympathectomy that terminates the sympathetic ganglia by clamping, excision, ablation, or transection with laser or cautery. The systemic treatment includes anticholinergic agents that inhibit synaptic acetylcholine, they interfere with neuroglandular signaling. Based on distribution channel, the global market for hyperhidrosis can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39308
In terms of geography, the hyperhidrosis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Furthermore, the North America hyperhidrosis market can be segmented into U.S., and Canada. The Europe hyperhidrosis market can be segregated into U.K., Germany, France, Italy, Spain, and Rest of Europe. The Asia Pacific Hyperhidrosis market can be further segmented into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. The Latin America hyperhidrosis market can be segmented into Mexico, Brazil, and Rest of Latin America. Where Middle East and Africa hyperhidrosis market is segmented into Saudi Arabia, South Africa, Israel, and Rest of Middle East and Africa. North America dominates the global hyperhidrosis market, followed by Europe. The prime factors that can be attributed to the expansion of the market in these regions are rising awareness about hyperhidrosis among the adult population and availability of sophisticated and technologically advanced treatment options. According to statistics published by International Hyperhidrosis Society, The U.S. has a prominent number of hyperhidrosis cases among the major developed countries. The stated prevalence rate for hyperhidrosis in the U.S. is about 4.8%. Hyperhidrosis affects nearly 15 million people in the U.S., and approximately 5% of the global population.
Key players operating in the global hyperhidrosis market include Allergan, Miramar Labs, Inc., Brickell Biotech, Inc., Dermira, Inc., Revance Therapeutics, Inc., GlaxoSmithKline plc, and TheraVida.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39308
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Gastroparesis Treatment Market Scope and Opportunities Analysis 2025
Gastroparesis, also known as delayed gastric emptying, can be defined as a disease of the stomach muscles or the nerves controlling these muscles that causes the stomach muscles to stop functioning. It affects the spontaneous movement of the stomach muscles. Impaired mobility of the stomach muscles leads to emptying of the stomach. Gastroparesis occurs due to damage to the vagus nerve either because of injury or illness. Gastroparesis that commonly occurs among people is known as idiopathic gastroparesis, indicating that the actual cause of the disease is unclear. Diabetes is other common cause of gastroparesis, as high blood sugar levels leads to slow damage of the vagus nerve causing gastroparesis. The common symptoms of the disease include nausea, feeling of fullness, gastroesophagial reflux, abdominal bloating, lack of appetite, and pain in the stomach area.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/gastroparesis-treatment-market.html
The global gastroparesis treatment market is anticipated to record moderate growth during the forecast period. Growth of the market can be attributed to increase in prevalence of diabetes mellitus among people, rise in number of surgeries being performed which could lead to post-operative gastroparesis, introduction of novel drugs, and focus of market players on research and development to launch specific drugs for the treatment of gastroparesis. Additionally, untapped opportunities in the emerging markets such as India and China are likely to fuel the growth of the market. However, usage of non-prescription drugs, side effects of available gastroparesis drugs, and stringent regulatory environment for the approval of new drugs are expected to restrain the market during the forecast period. Moreover, lack of awareness among people about gastroparesis and available treatments is anticipated to hamper market growth.
The global gastroparesis treatment market can be segmented based on drug class, type, distribution channel, and region. In terms of drug class, the market can be categorized into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment dominated the market in 2016, owing to effectiveness, ease of availability, high usage, and applicability of these medications in treating gastroparesis. Based on type, the global gastroparesis treatment market can be classified into diabetic gastroparesis, chronic gastroparesis, idiopathic gastroparesis, and post-operative gastroparesis. The post-operative gastroparesis segment is anticipated to expand at a rapid pace during the forecast period, owing to increase in the number of surgeries such as transplantation. In terms of distribution channel, the market can be divided into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment dominated the market in 2016 and the trend is anticipated to continue during the forecast period.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39305
Geographically, the global gastroparesis treatment market can be segmented into five major regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America was the largest market in terms of revenue in 2016 and the trend is anticipated to continue during the forecast period. Growth of the market in the region can be attributed to rise in the number of diabetic patients. Diabetic gastroparesis is considered one of the major forms of gastroparesis affecting the population. Europe is expected to be the next attractive market for gastroparesis treatment. However, sluggish economy in the region is likely to hamper the growth of the market. The market in Asia Pacific is anticipated to expand at a high CAGR owing to factors such as government focus on enhancing health care facilities, rise in patient population, and increase in product approvals.
Leading players operating in the global gastroparesis treatment market are Boston Scientific Corporation, Cardinal Health, Inc., C. R. Bard, Inc., Abbott Laboratories, Medtronic, Salix Pharmaceuticals, Inc., Janssen Global Services, LLC, Teva Pharmaceuticals, Kimberly-Clark Corporation, Rhythm Pharmaceuticals, Inc., Alfa Wassermann SPA, and Evoke Pharma, among others.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39305
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Behavioral Health Software Market Segmentation Detailed Study with Forecast to 2025
Behavioral health, more commonly referred to as mental health, can be defined as the scientific study of a person’s biology relating to mental well-being, emotions, concept of self, behavior, and ability to function in day to day life. All kinds of addictions anxiety, depression, and substance abuse fall under the realm of behavioral health. Behavioral health software can be defined as custom-built specialized software that is used by psychologists to understand behavioral patterns in patients and suggest treatment to deal with various behavioral issues such as anxiety, stress, addiction, and depression. It has the ability to retrieve laboratory, pharmacy, and radiology data observations on the patients being treated. Additionally, the software offers a detailed report addressing the individual patient’s needs.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/behavioral-health-software-market.html
The behavioral health software market is anticipated to be driven by increase in health care expenditure, rise in government funding for adoption of the software in health care facilities, focus of clinicians on providing quality care to patients, and the recurring requirement of support services for the software. Moreover, decline in the social stigma associated with behavioral health treatment is expected to boost the growth of the global behavioral health software market. However, lack of awareness about behavioral health software among clinicians in the emerging markets in Asia Pacific and Middle East & Africa, shortage of skilled psychologists, data security issues, rising concern related to data breaches, and privacy issues are expected to hamper the market in the near future.
The global behavioral health software market can be segmented based on component, functionality, delivery model, end-user, and region. In terms of component, the market can be classified into support services and software. The software segment can be further divided into integrated software and standalone software. Based on delivery model, the global behavioral health software market can be categorized into subscription model and ownership model. In terms of functionality, the market can be segmented into clinical, financial, and administrative. The clinical segment can be further segregated into telehealth, electronic health records (EHRs), clinical decision support systems, and others. The financial segment can be classified into revenue cycle management, managed care, and others. The administrative segment can be further divided into business intelligence, workforce management, case management, and others. Based on end-user, the global behavioral health software market can be segmented into payers and providers. The providers segment can be categorized into hospitals, clinics, and private practices.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39302
Geographically, the global behavioral health software market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the market in terms of revenue in 2016. The trend is anticipated to continue during the forecast period. Growth of the market in the region can be attributed to rise in number of patients with behavioral health issues, increase in adoption of behavioral health software, and high awareness among people. The market in Europe is anticipated to expand at a high CAGR during the forecast period owing to increase in access to behavioral health care, rise in incidence of behavioral disorders, and government initiatives for increasing awareness about behavioral health. Sluggish growth in Asia Pacific, Latin America, and Middle East & Africa can be attributed to the lack of awareness among people about behavioral health, lack of awareness among clinicians about behavioral health software, and social stigma associated with behavioral or mental health.
Leading players operating in the global behavioral health software market are Cerner Corporation, InSync Healthcare Solutions, Valant, Inc., Core Solutions, Inc., NextStep Solutions, Qualifacts, Netsmart Technologies, Advanced Data Systems Corporation, Mediware Information Systems, Welligent, Inc., Accumedic, and Compulink, among others.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39302
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Insulin Secretagogues Market - Latest Trends and Future Growth Study by 2025
Diabetes mellitus is not only a chronic disease itself, but it also augments various other chronic diseases such as cardiovascular diseases (increased threat of heart attack and congestive heart failure), renal failure, hepatic disorders, immunodeficiency, loss of vision, brain and nervous system disorders, and impaired injury healing time. Diabetes is broadly classified into type 1 and type 2 diabetes. Type 1 diabetes occurs most frequently in children and young adults, although it can occur at any age. Insulin is the hormone necessary for processing glucose. Type 1 diabetes was formerly known as ‘insulin-dependent diabetes mellitus.’ Hence insulin must be supplied to the patients with type 1 diabetes.Type 2 diabetes patients suffer from insulin resistance, which may be coupled with relative reduction in insulin secretion. The specific defects that lead to insulin resistance are unknown. Type 2 diabetes is the most common type of diabetes. It was formerly known as ‘non-insulin dependent diabetes mellitus. Insulin secretagogues, commonly known as insulin releasing pills, are a type of medicine for type 2 diabetes. People suffering from type 2 diabetes fail to make enough insulin to maintain normal blood glucose levels. Insulin secretagogues stimulate the pancreas to secrete insulin in type 2 diabetes patients. Sulphonylureas, a type of insulin secretagogue, was developed in 1920s and has been effectively used to manage type 2 diabetes. Sulphonylureas enhances the sensitivity of beta cells to glucose and thus stimulates pancreas to secrete insulin.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/insulin-secretagogues-market.html
The global insulin secretagogues market is expected to expand at a significant pace during the forecast period. Type 2 diabetes is primarily caused by lifestyle factors such as poor diet, obesity, stress, lack of physical activity, and urbanization. Genetics can also determine predisposition to type 2 diabetes. High prevalence of type 2 diabetes is the key factor for expansion in the global insulin secretagogues market. According to various studies, its prevalence varies from 90% to 95% across the globe. Aging population is expected to increase the incidence of type 2 diabetes, which is likely to drive the global insulin secretagogues market. Certain side effects such as hypoglycemia and weight gain are associated with the long term use of insulin secretagogue.
The global insulin secretagogues market can be segmented based on type, distribution channel, and region. In terms of type, the market can be divided into sulfonylureas and glinides. Sulfonylureas can be further split into first generation sulfonylureas and second generation sulfonylureas. First generation sulfonylureas comprise drugs such as Tolbutamide and Chlorpropamide. Second generation sulfonylureas comprise drugs such as Glimepiride, Glipizide, and Glyburide. Glinides include drugs such as Repaglinide and Nateglinide. These drugs cause inhibition of potassium efflux, causing depolarization and release of insulin from pancreatic β-cells. Based on distribution channel, the global insulin secretagogues market can be classified into hospital pharmacies, online pharmacy, retail pharmacy, and diabetes clinics.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39299
Geographically, the global insulin secretagogues market can be segmented into five major regions: North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America and Europe dominate the global insulin secretagogues market due to high prevalence of diabetes in these regions. Asia Pacific is a highly attractive market for insulin secretagogue. A significant proportion of the population in India and China is diabetic. Also, increase in awareness about insulin secretagogue is fueling the growth of the market in the region. Latin America and Middle East & Africa are emerging markets for insulin secretagogue. The market in these regions is expected to expand at a significant pace during the forecast period.
Key players in the global insulin secretagogues market include Kissei Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, and Biocon Ltd.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39299
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Acute Otitis Media (AOM) Treatment and Management Market Share and Growth Factors Impact Analysis 2017 - 2025
Acute otitis media (AOM) is a common infection, which usually affects children. The disease leads to inflammation of middle-ear forming a middle-ear infusion. It is the second most common disease in children after upper respiratory tract infection. The disease exhibits symptoms such as fever, ear discharge (otorrhoe), irritability, and otalgia. Acute otitis media (AOM) affects approximately 80% children aged between 1 year and 5 years. Globally, the cumulative incidence rate of acute otitis media is 10.85%. Around 709 million cases of acute otitis media are reported across the world each year, of these 51% occur in children aged under five years. Children between 6 months and 18 months are at a high risk of getting the disease. If the disease is left untreated, it could lead to permanent hearing loss. Repeated acute otitis media episodes in an individual can result into severe complications such as hearing loss/impairment, intracranial infection, and facial paralysis. Bacteria and viruses are the causative agents of this infection. Streptococcus pneumoniae is the major pathogen responsible for this infection. Around 35% to 55% cases of acute otitis media are caused due to bacteria and about 20% to 30% cases of acute otitis media are due to viruses.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/acute-otitis-media-treatment-management-market.html
Rise in incidence of acute otitis media cases drives the global acute otitis media treatment and management market. Other factors such as increase in young maternal age, children with aboriginal ancestry, and rise in number of women who smoke during pregnancy lead to rise in the number of acute otitis media cases. This in turn propels the global acute otitis media treatment and management market. However, frequent use of antibiotics in treating acute otitis media is giving rise to antibiotic resistant strains restricting the use of certain drugs in the treatment of the disease. This hampering the growth of the acute otitis media treatment and management market.
The global acute otitis media treatment and management market can be segmented based on type of medical care therapy, type of surgical care, distribution channel, and region. In terms of type of medical care therapy, the market can be categorized into antimicrobial therapy, antihistamine-decongestants drugs therapy, steroid therapy, and mucolytic drugs therapy. Based on type of surgical care, the global acute otitis media treatment and management market can be classified into tympanocentesis, myringotomy, and myringotomy. In terms of distribution channel, the market can be divided into hospitals, ENT specialist clinics, retail pharmacies, and online pharmacies.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39296
Geographically, the global acute otitis media treatment and management market can be segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Incidence rate of acute otitis media is high in countries in the Middle East. Saudi Arabia has a high number of children affected with the disease. In less developed countries, the disease is quite common and one of the major causes of childhood mortality. Poor hygiene facilities, less health care infrastructure, and lack of awareness are the major causes of high cases of acute media otitis in the less developed and under developed nations. Increase in awareness about the disease and rise in incidence rate in other parts of the globe boost market growth. Moreover, the unmet medical need presents an opportunity for all research and development programs to invest in the global acute otitis media treatment and management market.
Key players in the global acute otitis media treatment and management market include Eli Lilly and Company, Pfizer, Inc., Abbott, GlaxoSmithKline plc, Janssen Pharmaceuticals, Sanofi, Bayer AG, Novartis AG, Astellas Pharma, Inc. and Bristol Myers Squibb Company.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39296
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Myoclonus Drugs Market Competitive Landscape Analysis with Forecast by 2025
Myoclonus is a symptom rather than a disease. It is described as involuntary jerking of a muscle. It is caused by sudden muscle contractions known as positive myoclonus. Myoclonus caused by muscle relaxation is called negative myoclonus. Myoclonic jerks could occur in sequence, alone and in a pattern, or without pattern. Myoclonus can be classified into action myoclonus, cortical reflex myoclonus, palatal myoclonus, essential myoclonus, reticular reflex myoclonus, progressive myoclonus epilepsy (PME), sleep myoclonus, and stimulus-sensitive myoclonus. Action myoclonus is muscular jerking triggered or intensified by voluntary movement.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/myoclonus-drugs-market.html
Myoclonus can be caused by underlying conditions such as shakes or spasms due to anxiety or exercise, infant muscle twitching during sleep or after feeding, lipid storage disease, chemical or drug poisoning, autoimmune inflammatory conditions, Parkinson's disease, Lewy body dementia, Alzheimer's disease, multiple system atrophy, Creutzfeldt-Jakob disease, and stroke. People with myoclonus often describe their symptoms and signs as shakes or spasms and jerks that are brief, shock-like, sudden, involuntary, variable in intensity and frequency, and sometimes severe enough to interfere with eating, speaking, or walking. Neurology professionals diagnose myoclonus with the help of these signs and symptoms. They also use electroencephalography (EEG), electromyography (EMG), magnetic resonance imaging (MRI), and laboratory tests such as autoimmune disease, kidney or liver disease, metabolic disorders, and others. Generally, myoclonus is managed by tranquilizers and anticonvulsants. Levetiracetam (Keppra), primidone (Mysoline), and valproic acid (Depakene) are anticonvulsants that reduce myoclonus symptoms. Clonazepam is a more common tranquilizer used for myoclonus. According to PubMed literature review, prevalence of myoclonus was 4 cases per 100,000 in Japan in 2011. Prevalence of the condition increases with age.
Increase in research and development, introduction of novel disease therapies, rise in demand for effective therapies among patients, and surge in disease prevalence are projected to fuel the growth of the global myoclonus drugs market. Rise in prevalence of chronic diseases such as cardiovascular, neurovascular, and arthritis, and increase in health care insurance coverage are the other factors likely to accelerate the growth of the global myoclonus drugs market.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39293
The global myoclonus drugs market can be segmented based on drug type, distribution channel, and region. In terms of drug type, the market can be categorized into tranquilizers, botulinum toxin (Botox), and anticonvulsants. Botulinum toxin can help treat myoclonus where a discrete body part is affected. Based on distribution channel, the global myoclonus drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. In term of revenue, the hospital pharmacies segment dominated the global myoclonus drugs market in 2016.
Geographically, the global myoclonus drugs market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for myoclonus drugs. In terms of revenue, the U.S. holds a major share of the market in North America. The market in Europe is expanding rapidly due to high prevalence of myoclonus in the region. The myoclonus drugs market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to the growth of the market in Asia Pacific between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and rise in awareness among the people. Brazil and Mexico dominate the market in Latin America. South Africa, Turkey, and other developing countries in Middle East & Africa contribute to the growth of the myoclonus drugs market in MEA. Key players operating in the myoclonus drugs market include Allergan plc, Pfizer, Inc., GlaxoSmithKline plc, Wockhardt Ltd.., Teva Pharmaceutical Industries Ltd, Novartis AG, Johnson & Johnson, Cephalon, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39293
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Carpal Tunnel Syndrome Treatment Market Current Trends and Future Aspect Analysis 2017 - 2025
Carpal tunnel syndrome is a medical condition of numbness, weakness, and tingling in the hand due to compression of the median nerve in the wrist. The median nerve is located on the palm side and also known as the carpal tunnel. This nerve is responsible for sensation in the thumb, the index finger, the middle finger, and part of the ring finger. The key work of the median nerve is to supply the impulse to the thumb muscle. Excess pressure in the wrist and the median nerve causes swelling. Some other frequent conditions associated with carpal tunnel syndrome are thyroid dysfunction, high blood pressure, diabetes, and autoimmune disorders such as rheumatoid arthritis. The most common signs and symptoms of carpal tunnel syndrome are tingling, numbness, pain in the thumb, pain and burning that travels up to the arm, weakness in the muscles of the hand, and the wrist pain at night that interferes with sleep. Health care specialists recommend nerve conduction studies, physical examination, and other tests to confirm the presence of carpal tunnel syndrome. According to the National Institute for Occupational Safety & Health (NIOSH), more than 230,000 procedures are performed for carpal tunnel surgery every year. Approximately 23% of people with carpal tunnel syndrome are able to resume their profession after the surgery. Usually, women are more affected by carpal tunnel syndrome than men. More than 8.3 million people are diagnosed with carpal tunnel syndrome every year.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/carpal-tunnel-syndrome-treatment-market.html
Increasing research and development activities, introduction of innovative therapies, rising demand for effective therapies among patients, and growing disease prevalence are projected to fuel the global carpal tunnel syndrome treatment market in the near future. Lifestyle factors such as smoking, high body mass index (BMI), sedentary lifestyle, and high salt intake may increase the risk of developing carpal tunnel syndrome. Jobs that involve repetitive movement of the wrist such as manufacturing, keyboard operating, assembly line work, and construction work raise the risk of developing carpal tunnel syndrome. Increasing health care insurance coverage is another factor likely to drive the global carpal tunnel syndrome treatment market during the forecast period.
The global carpal tunnel syndrome treatment market can be segmented based on treatment type, distribution channel, and region. In terms of treatment type, the market has been categorized into medications, physical and integrative therapies, and surgery. Based on distribution channel, the market has been classified into hospital pharmacy, retail pharmacy, and online pharmacy. In term of revenue, the hospital pharmacy segment dominated the carpal tunnel syndrome treatment market in 2016.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39290
Geographically, the global carpal tunnel syndrome treatment market has been segmented into five regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for carpal tunnel syndrome treatment. In terms of revenue, the U.S. holds a major share of the North America market. The market in Europe is expanding rapidly, due to high prevalence of carpal tunnel syndrome in the region. The market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to growth of the Asia Pacific market between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and rise in awareness among people in these countries. Brazil dominates the Latin America market for carpal tunnel syndrome treatment. South Africa, Turkey, and other developing countries in Middle East & Africa contribute to growth of the MEA market.
Key players operating in the global carpal tunnel syndrome treatment market are Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb and Company, Wockhardt Ltd., Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Mylan Pharmaceuticals, Inc. and Aurobindo Pharma Ltd.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39290
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Alpha-glucosidase Inhibitor Drugs Market Size, Status and Forecast to 2025
Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibitor drugs help in delaying glucose absorption and slow the digestion of carbohydrates. This results in lower rise of glucose in the blood after meals and remains effective throughout the day.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/alpha-glucosidase-inhibitor-drugs-market.html
Alpha-glucosidase inhibitor drugs help in the treatment of dumping syndrome and type 2 diabetes. Dumping syndrome is a disease in which the food in the stomach is emptied rapidly into the small intestine. This results in drawing excess of fluid from the partially digested food into the small intestine that causes palpitations, faintness, sweating, diarrhea, cramping, and nausea. Dumping syndrome normally occurs in people who consume excess of refined or simple sugar, specifically in the people who had surgery done to remove or modify the stomach. Type 2 diabetes is also known as insulin resistance due to body cells not being able to respond appropriately in the presence of hormone insulin. It is more complex than type 1 diabetes, however, it is sometimes easier to treat. Undiagnosed type 2 diabetes, may cause severe complications that include coronary artery disease and renal failure.
Growth in geriatric population across the world boosts the demand for alpha-glucosidase inhibitor drugs as elderly people are more prone to diseases such as type 2 diabetes. Furthermore, rising disposable income increases the demand for alpha-glucosidase inhibitor drugs. Sedentary lifestyle of people and changing environmental conditions are the drivers of the global alpha-glucosidase inhibitor drugs market. Moreover, strong inheritable genetic connection in type 2 diabetes propels the market for alpha-glucosidase inhibitor drugs. Increasing cases in obesity and chronic obesity also leads to chances of development of type 2 diabetes, which in turn, drives the growth of the global alpha-glucosidase inhibitor drugs market. Increasing stomach surgeries due to stomach cancer boosts the demand for the alpha-glucosidase inhibitor drugs. According to the World Health Organization (WHO), in 2015, there were 754000 deaths due to stomach cancer.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39287
The global alpha-glucosidase inhibitor drugs market can be segmented on the basis of disease type, distribution channel, and region. Based on disease type, the global alpha-glucosidase inhibitor drugs market can be categorized into dumping syndrome and type 2 diabetes. In terms of the distribution channel, the global alpha-glucosidase inhibitor drugs market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global alpha-glucosidase inhibitor drugs market can be divided into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America constituted a major share of the alpha-glucosidase inhibitor drugs market in 2016 due to increasing prevalence of type 2 diabetes in the region. According to researches, more than 95% of the population in North America is suffering from type 2 diabetes and approximately 20% of this population is over the age of 65. Europe accounted for the next leading share of the alpha-glucosidase inhibitor drugs market in 2016 due to increasing disposable income and high investments in research and development of alpha-glucosidase inhibitor drugs in the region. The alpha-glucosidase inhibitor drugs in Asia Pacific is anticipated to expand during the forecast period owing to increasing awareness about alpha-glucosidase inhibitor drugs, and investments made by key players to penetrate the emerging countries of the region, especially India and China. The alpha-glucosidase inhibitor drugs market in Latin America and Middle East & Africa is also expected to expand during the forecast period owing to increasing government initiatives in the regions. Key players of the global alpha-glucosidase inhibitor drugs market include Pfizer Inc. and Bayer AG.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39287
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Aldosterone Receptor Antagonist Drugs Market Research Report by Geographical Analysis and Forecast to 2025
Aldosterone receptor antagonist drugs are also known as MRAs, MCRAs, and anti-mineralocorticoids. Aldosterone receptor antagonist drugs are a drug class that inhibit the effects of aldosterone. Adrenal cortex of the adrenal gland produces a primary mineralocorticoid hormone, called aldosterone, in the body. Aldosterone increases sodium reabsorption by the colon, sweat glands, salivary glands, and kidneys. Aldosterone also increases excretion of potassium and hydrogen ions. Aldosterone receptor antagonist drugs block the effects of aldosterone, which means the aldosterone receptor antagonist drugs block the reabsorption of sodium that encourages water loss. This effect of blocking helps reduce the fluid around the heart, and thereby decreases elevated blood pressure in the patient’s body. Aldosterone receptor antagonist drugs are used for the treatment of heart failure, and high blood pressure in patients. Aldosterone receptor antagonist drugs also cause increase in passage of urine.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/aldosterone-receptor-antagonist-drugs-market.html
Aldosterone receptor antagonist drugs also help in the primary diagnosis and treatment of hyper-aldosteronism, hypokalemia, hirsutism, gender dysphoria, edema, alopecia, and acne. Acne is an inflammation of the skin that is characterized by superficial skin eruptions around the hair follicles. Alopecia is baldness, the absence of hair on the areas of the skin, where it should actually be present. Loss of hair as a result of radiation or chemotherapy administered to the head. Loss of hair from chemotherapy is temporary. Loss of hair from radiation is usually permanent.
Edema is the abnormal presence of fluid in large amounts in the intercellular tissue spaces of the body, usually demonstrable excessive fluid is accumulated in the subcutaneous tissues. Edema is localized, to increased vascular permeability, or lymphatic or venous obstruction. Edema is systemic, due to renal disease or heart failure. The designation of edema fluid is according to the site where the fluid is collected; for example, ascites. Gender Dysphoria is also called as gender identity disorder. It is a disorder where the person identifies himself or herself as the opposite gender. For example, a person who is a girl may actually act, and feel like a boy. The person feels very uncomfortable with the gender that they are actually born as.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39284
Heart failure is the inability of the heart to pump blood, which contains nutrients and oxygen, to rest of the body. Hirsutism is the abnormal distribution of hair; for example, male pattern of hair distribution in women. Hypokalemia is a condition when the levels of potassium in serum or blood decrease or fall below permissible levels, which leads to various disease conditions. Primary hyper-aldosteronism is a disease condition where the hormone aldosterone is released in excess amounts by the adrenal glands. Increasing prevalence of primary hyper-aldosteronism diagnosis, in treatment of heart failure, high blood pressure, primary hyper-aldosteronism, hypokalemia, hirsutism, gender dysphoria, edema, alopecia, and acne boosts the demand for aldosterone receptor antagonist drugs. Increasing demand for the drugs is due to the growing geriatric population across the globe.
The global aldosterone receptor antagonist drugs market can be segmented based on disease type, distribution channel, and region. In terms of disease type, the market can be divided into heart failure, high blood pressure, primary hyper-aldosteronism, hypokalemia, hirsutism, gender dysphoria, edema, alopecia, and acne. Based on the distribution channel, the market can be classified into online pharmacies, retail pharmacies, and hospital pharmacies.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39284
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Point of Care (POC) Data Management Systems Market Research Report by Key Players Analysis 2025
Point of care testing (POCT) refers to the medical diagnostic tests performed at the site or near patients for immediate clinical decision making. Managing patients’ test data and recording it for regulatory compliance have been tedious tasks for medical professionals. Several companies have developed POC data management systems in order to help medical professionals overcome challenges while maintaining patient records. POC data management systems facilitate the recording, storage, and viewing of patients’ medical records from multiple point of care devices at central data management systems. Additionally, these provide a bidirectional interface to both hospitals and laboratory professionals on a single enterprise platform. POC data management systems offer features such as recording of the patients’ medical records, downloading of POCT device data, and integration of data with the hospital information system (HIS), and laboratory information system (LIS). POC data management systems have several advantages over manual data recording systems such as reduced paperwork, increased work efficiency of testing procedures, continuous monitoring of point of care devices, centralized operator management, and many others.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/point-care-data-management-systems-market.html
The global point of care (POC) data management systems market is primarily driven by increase in adoption of POC devices by hospitals and laboratories. Increase in geriatric population, high incidence of chronic as well as infectious diseases, and rise in awareness among people about preventive health care has led to high demand for point of care testing devices across the world. Rapidly improving health care facilities and infrastructure in developing countries, increase in number of hospitals and diagnostics laboratories, and surge in health care budgets are projected to fuel demand for point of care data management systems during the forecast period. Moreover, technological advancements in data management systems such as remote monitoring, data integration into central hospital information systems, wireless connectivity, process automation, ease of use, and web tutorials are factors augmenting demand for POC data management systems. However, high cost of POC data management systems and slow rate of adoption are likely to hamper the market in the near future.
The global point of care data management systems market can be segmented based on component, mode of delivery, end-user, and region. In terms of component, the global market can be classified into hardware and software. The hardware segment is expected to account for a leading share of the global market. The software segment is estimated to expand at a high CAGR during the forecast period. Based on mode of delivery, the global point of care data management systems market can be divided into web-based systems, cloud-based systems, and on-premises data management systems. The on-premises data management systems segment is anticipated to dominate the global market by 2025. In terms of end-user, the global point of care data management systems market can be categorized into hospitals and physicians clinics and diagnostics laboratories.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39281
Geographically, the global point of care data management systems market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for significant shares of the global market and are projected to gain market share by 2025. Large share of these regions is attributed to well-established health care facilities, high health care infrastructure budgets, increase in incidence of lifestyle diseases, and rise in demand for preventive health care. The POC data management systems market in Europe is estimated to expand at a significant pace during the forecast period. The market in Asia Pacific is expected expand at a rapid pace during the forecast period The POC data management systems markets in Latin America and Middle East & Africa is likely to expand at a moderate pace.
Key players operating in the global point of care (POC) data management systems market include Siemens Healthineers, HemoCue AB, Abbott Laboratories, Radiometer Medical ApS, TELCOR, Inc., Thermo Fisher Scientific, Inc., Randox Laboratories Ltd., Esaote SpA, Hedera Biomedics srl, and Seaward Electronic Ltd.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39281
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Wearable Vital Signs Measurement Devices Market Key Manufacturers, Development Trends And Competitive Analysis 2025
Vital signs monitoring devices monitor vital parameters such as blood pressure, heart rate, respiratory rate, oxygen saturation, blood glucose level, and body temperature. Apart from this, monitoring of various other additional signs such as urinary continence, pain, gait speed, shortness of breath, end-tidal carbon-dioxide, etc. are also considered in vital signs measurement depending on the severity of the disease. These devices record information of the patient’s health status time to time and helps to keep track of disease control and treatment progress. They also help minimize the risk of treatment errors and wrong diagnosis. With evolution of technology, wearable vital sign measurement devices are now available in different modalities, attractive designs, and innovative features such as increased battery life, monitoring of more than one parameter by using a single device.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/wearable-vital-signs-measurement-devices-market.html
Increasing healthcare awareness, rising healthcare expenditure, and technological advancements are some of the factors fueling growth of the wearable vital sign measurements market. Moreover, innovative solutions offered by leading vendors in the global wearable vital signs measurement devices market to increase the wearing comfort at affordable prices is boosting the growth of the wearable vital sign measurement devices market. However, development of the system with minimal size, and maximum battery life are the factors delaying entry of new products into the market. Moreover, high cost of the products is restraining the growth of the market in developing countries.
The global wearable vital signs measurement devices market can be segmented based on product type and distribution channels. On the basis of product type, the wearable vital sign measurement device market can be categorized into blood pressure monitoring devices, ECG recorder, ECG holter, pulse oximeter, sleep monitor for Obstructive Sleep Apnea (OSA), thermometer, BP tracker, respiration rate measuring devices, respiration effectiveness monitoring devices, body-worn smart clothing, and continuous blood glucose level monitoring devices. Among these, blood pressure monitoring devices, thermometers, and continuous blood glucose monitoring devices are gaining highest market share owing to increasing prevalence of hypertension and diabetes due to changing lifestyles. In terms of distribution channels, the market can be classified into retail sellers and e-commerce.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39272
Geographically, the global wearable vital signs measurement devices market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these regions, North America continues to be the most profitable for vendors operating in the global wearable vital sign measurement devices market owing to significant adoption of technologically advanced products, presence of large number of manufacturers located in the U.S., and high healthcare spending in this region. Europe is the second largest market for wearable vital sign measurement devices owing to increasing geriatric population, growing awareness about physiological fitness among the people in this region leading to rising demand for health monitoring devices, and high per capita spending capacity. Asia Pacific and Latin America are expected to be most lucrative markets for wearable vital sign measurement devices attributed to growing economies, growing population, increasing incidence of lifestyle diseases such as high blood pressure, diabetes, and obesity caused by changing life styles.
The key players operating in the global wearable vital signs measurement devices market include CareTaker LLC., Vital Connect, TDK Corporation, Alere, Nokia, Viatom Technology, GYMWATCH GmbH, Medtronic, Vivometrics Inc, Masimo, and custo med GmbH.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39272
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Novel Drug Reconstitution Systems Market to 2025 Size, Share & Trend | Industry Analysis Report
Drug reconstitution can be a challenging task for non-professionals managing a chronic illness. The dosage forms should ideally be easy to administer, safe, and cost-effective. However, in order to ensure chemical and physical stability of the product, most drugs are formulated in the lyophilized form to be reconstituted at the time of administration. The lyophilized form maintains drug stability and efficacy during the shelf-life period and reduces the time required to make products stable in liquid dosage forms. This enables rapid entry of a new drug into the market, maintaining the market competitiveness. Reconstitution and mixing was a tedious job earlier; however, technological advancements have resulted in the development of novel drug reconstitution systems, making the reconstitution process easier with minimum dosing errors. These systems are highly preferred by patients, as they are well-engineered to reduce their efforts and help them stick to the dosage regimen. Selecting the right reconstitution alternative depends upon the type of drug, the diluent volume type, the administration method, and overfill issues.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/novel-drug-reconstitution-systems-market.html
Growing research and development activities by pharmaceutical and biopharmaceutical vendors, rising prevalence of several chronic diseases, increasing health care expenditure worldwide, and benefits of novel drug reconstitution systems are factors driving the global novel drug reconstitution systems market. Reconstitution systems offer several advantages such as ease of administration, reduced drug loss, decreased need for overfilling by manufacturers, improved safety, and better patient compliance. Moreover, increasing inclination toward self-administration of drugs and increasing trend of development of patient-centric drug delivery systems by manufacturers are expected to boost the global novel drug reconstitution systems market during the forecast period. However, increased costs of products led by introduction of novel techniques and stringent regulatory requirements are factors restraining the global novel drug reconstitution systems market.
The global novel drug reconstitution systems market can be segmented based on product, distribution channel, and region. In terms of product, the market can be categorized into vial adaptors, vial-to-vial systems, needleless transfer devices, direct connection to vial devices, and dual chamber syringes. Vial adapters are quick, safe, and cost-effective. They improve the reconstitution performance. A vial adapter contains a syringe with or without diluent filled in it and a vial containing lyophilized drug. The vial-to-vial system comes with an adapter connecting two vials. This is an attractive type of novel drug reconstitution system, as it does not require needles. The direct connection to vial devices enables manufacturers to design a compact packaging for the product. In terms of distribution channel, the global novel drug reconstitution systems market can be segmented into hospital pharmacy, retail pharmacy, and e-commerce system. The retail pharmacy segment is expected to hold the maximum market share by the end of the forecast period. The e-commerce segment is anticipated to expand at the maximum CAGR during the forecast period.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39269
Geographically, the global novel drug reconstitution systems market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global novel drug reconstitution systems market, owing to growing incidence of chronic diseases, high adoption of technologically advanced products in the region, high health care expenditure, and growing R&D activities to develop novel products to enhance patient comfort by players in the U.S. Europe is the second-largest market for novel drug reconstitution systems, due to growing geriatric population, increasing investments in R&D activities, and rising adoption of novel drug delivery systems to treat chronic conditions. Asia Pacific is considered as an emerging market for novel drug reconstitution systems, owing to presence of developing economies, increasing health care expenditure, and constantly rising population in the region.
Key players operating in the global novel drug reconstitution systems market are West Pharmaceutical Services, Inc., Integrity Bio, Inc., Sensile Medical AG, Yukon Medical, Nemera, Credence MedSystems, Inc., Alkermes, and Baxter.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39269
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Digital Mammography Market to Witness a Pronounce Growth by 2025
Mammography is the diagnostic evaluation of breast tissues to detect the presence of carcinogenic cells. The evaluation is performed by using lower doses of X-rays and ionizing radiations. The use of X-ray detectors in the digital mammography has enabled formation of clearer images as compared to those obtained by using the film screen mammography technique. The digital mammography has been useful in the detection of cancer even before a woman experiences symptoms of cancer. The system can detect changes in the breast tissues even before the physician or the patient actually feels the presence of a tumor. In the digital mammography, photons are converted into light, which is then converted into a digital signal that gets displayed on a screen. According to Susan G. Komen, a Breast Cancer Organization, since the discovery of mammography as a breast cancer detection tool in the 1980s, the number of procedures performed increased tremendously (by 70%) till 2000. Worldwide, women are more affected by breast cancer than men. The risk of breast cancer doubles after the menopause, as a majority of breast cancer sub-types are hormone-related. According to the American Cancer Society, about 252,710 new cases of invasive breast cancer are estimated to be diagnosed in women in the U.S. by the end of 2017.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/digital-mammography-market.html
Growing awareness about breast cancer, government initiatives to encourage early detection of breast cancer and breast-related disorders, changing lifestyle leading to hormonal changes in women (such as early menarche, child bearing after the age of 30, or not bearing any child), rising geriatric population, and technological advancements such as breast tomosynthesis are factors driving the global digital mammography market. However, limitations regarding flat images formed by using the 2-D full-field digital mammography and risk of exposure to radiations are factors restraining the global mammography systems market.
The global digital mammography market can be segmented based on product, end-user, and region. In terms of product, the market can be categorized into 2-D full-field digital mammography tomosynthesis and 3-D full-field digital mammography tomosynthesis. The 3-D full-field digital mammography tomosynthesis segment is expected to expand at the maximum CAGR during the forecast period, owing to high-quality images produced. In terms of end-user, the global digital mammography market can be divided into hospitals, cancer clinics, gynecology clinics, ambulatory surgery centers (ASCs), and diagnostic imaging centers. Hospitals and diagnostic imaging centers are leading segments of the market. They are expected to hold the maximum market share during the forecast period.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39266
Geographically, the global digital mammography market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, North America dominates the global digital mammography market, owing to adoption of technologically advanced mammography units by diagnostic imaging centers and hospitals, and expanding reimbursement coverage by governments and sophisticated health care facilities in the region. According to the American Cancer Society, in the U.S., breast cancer is a highly prevalent disease among women. About 12% of women are estimated to be diagnosed with breast cancer in the country by the end of 2017. Europe is the second largest market for digital mammography, owing to government funding for breast cancer and improved reimbursement policies in the region. The full-field digital mammography tomosynthesis segment of the market in developed countries in the West is expected to expand at a higher CAGR as compared to that of the market in developing countries during the forecast period, due to its high average selling price (ASP), high cost of image storage, and requirement for a sophisticated maintenance facility. Asia Pacific is an emerging market for digital mammography, owing to growing healthcare awareness, increasing number of breast cancer cases in China and India, and changing health care infrastructure in the region.
Key players operating in the global digital mammography market are Hologic, Inc., FUJIFILM Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., GENERAL ELECTRIC, Analogic Corporation, Konica Minolta, Inc., Planmed Oy, BET Medical, and Carestream Health.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39266
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Needleless IV Access Valves & Accessories Market: Growth and Sales Forecast 2017 - 2025
Needleless syringes or connectors are used for protecting health care personnel from needlestick injuries that may occur while connecting multiple intravenous (IV) access syringes, catheters, and/or sets. The use of needleless or needle-free access valves and accessories in different types of syringe systems, catheters, and intravenous access systems has started. Depending on its design and type of usage, these devices are referred to as injection caps, injection ports, end caps, luer-activated devices, or mechanical valves. Presently, different types of needleless intravenous access valves and accessories are available in the market, which differ in terms of appearance and usage characteristics. The external covering of a needleless connector can be transparent, opaque, or colored and the linking surface can possess an angled core or it can be flat or concave.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/needleless-iv-access-valves-accessories-market.html
Major driving factors for the needleless IV access valves & accessories market are increasing incidence of needlestick injuries among health care workers, rising demand for better and more appropriate needleless systems, and increasing awareness about benefits associated with these devices. According to the Occupational Safety & Health Administration, every year, 384,000 needlestick injuries and other sharps-related injuries are sustained by hospital-based health care personnel. This means an average of around 1,000 sharps-related injuries occur every day in the U.S. hospitals. However, these needleless systems have been associated with increase in complications such as catheter lumen occlusion and catheter-related bloodstream infection (CRBSI), which may restrain the market during the forecast period.
The needleless IV access valves & accessories market has been segmented based on product, end-user, and geography. In terms of product, the needleless IV access valves & accessories market has been divided into access valves and accessories. The access valves segment has been sub-categorized into low-pressure valves, normally closed valves, dual-check valves, and others. Based on end-user, the needleless IV access valves & accessories market has been segmented into hospitals, clinics, ambulatory surgical centers, and others.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39263
In terms of geography, the global needleless IV access valves & accessories market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global market, owing to increasing demand for technological advanced products, favorable government initiatives, and rising prevalence of needlestick injuries. According to Occupational Safety & Health Administration, currently 5.6 million workers in the U.S. health care industry are at a risk of occupational exposure to blood-borne pathogens via needlestick injuries or other sharps-related injuries. Europe is the second-largest market for needleless IV access valves & accessories, owing to high demand for advanced needleless technologies and equipment, high awareness about well-established health care systems, and availability of workforce with the required skills or knowledge to use of IV access systems. Increasing adoption of and growing awareness about technologically advanced products, development of infrastructure, increasing health care expenditure, and rising disposable income are some of the factors that are projected to drive the needleless IV access valves & accessories market in Asia Pacific during the forecast period. Countries such as Brazil and Mexico are expected to contribute to growth of the market in Latin America during the forecast period, due to rising disposable income of the people and improving medical infrastructure in these countries.
Major players operating in the needleless IV access valves & accessories market are B. Braun Melsungen AG, Smiths Medical, Baxter, BD, Pfizer Inc., ICU Medical, Inc., Vygon, Henry Schein, Inc., CODAN Medizinische Geräte GmbH & Co KG, and CAIR LG.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39263
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
High-sensitivity Electrocardiograph (hsECG) Testing Devices Market Detailed Study Analysis with Forecast by 2025
The resting electrocardiogram (ECG) has been widely used as a cardiac monitoring system. However, the growing complexity in medical conditions has led to rising technology demands from consumers for enhanced mobility, ease of usage, interoperability, and streamlined workflow so that the data can easily be accessed with electronic medical records and enable physicians to accurately diagnose and treat the condition. Growing incidence of cardiovascular diseases has augmented demand for innovative devices for front-line testing of patients in its diagnosis and treatment. High sensitivity ECG testing devices hold significant promise for improvement in the detection of cardiac disease when compared to resting electrocardiogram (ECG) devices.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/high-sensitivity-electrocardiograph-testing-devices-market.html
Three major categories of cardiac disease include arrhythmia, structural heart disease, and coronary artery disease (CAD).The current resting electrocardiogram (ECG) devices, which function with traditional technology have several limitations in terms of detection of structural and CAD disease. Conventional resting ECG devices are unable to detect CAD in 50% of patients, leaving a large pool of patients undiagnosed. Current healthcare guidance does not recommend the use of resting ECG in asymptomatic patients. This has created a diagnostic gap for early detection of heart diseases. hsECG could play a significant role in early preventative treatment and diagnosis of many healthcare systems and thus reduce unnecessary healthcare expenditures. hsECG devices use an advanced form of signal processing called continuous wavelet transform, to transfer ECG signals into energy distribution during the cardiac cycle. Traditional ECG only examines analog waveforms of signals. The use of advanced form of signal processing increases the sensitivity of detection in the device for the presence of cardiac disease. A clinical trial conducted by HeartScience among 200 patients showed that the devices resulted in 87% specificity and 88% sensitivity in detection of cardiac dysfunction in the diastolic phase of the cardiac cycle. The advantages of hsECG over resting ECG, growing cardiovascular disease, and high prevalence of CAD worldwide is likely to drive the high-sensitivity electrocardiograph (hsECG) testing devices market.
The global high-sensitivity electrocardiograph (hsECG) testing devices market has been segmented based on applications, end-user, and region. In terms of applications, the market has been segmented into coronary artery disease (CAD), structural disease, arrhythmia, and others. Based on end-user, the market has been classified into hospitals, diagnostic centers, clinics, and ambulatory surgical centers. Hospitals segments is likely to dominate the market during the forecast period, owing to rising prevalence of cardiovascular disease and growing number of procedures of cardiac surgeries in hospitals.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39260
Geographically, the global high-sensitivity electrocardiograph (hsECG) testing devices market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The only hsECG devices developed by HeartScience is under regulatory approval in Australia, Canada, Latin America, the Middle East, and Asia Pacific and the U.S. However, during the forecast period, North America is likely to expand at the highest CAGR in the global high-sensitivity electrocardiograph (hsECG) testing devices market. Strong product pipeline, presence of established players of the parent ECG device market in the U.S., and growing prevalence of cardiac disease in North America is anticipated to drive the market growth of high-sensitivity electrocardiograph (hsECG) testing devices in North America. Europe is anticipated to register the second highest growth in the high-sensitivity electrocardiograph (hsECG) testing devices market during the forecast period owing to early approval of high-sensitivity electrocardiograph (hsECG) testing devices in Europe and ease of availability of these devices for European cardiologists due to strong sales and distribution channels of manufacturers in Europe.
The key player operating in the global high-sensitivity electrocardiograph (hsECG) testing devices market is HeartScience. The product developed by HeartScience has received CE approval and will be soon available in the Europe market. The product is expected to be submitted for FDA approval in 2018. The company is seeking to receive regulatory approval in the Asia Pacific market in 2018.
Request Table of Content of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=39260
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes
Text
Forecast and Analysis on Brain Aneurysm Treatment Market for Period 2017 - 2025
Brain aneurysm is a bulging or balloon-like growth in humans, which appears typically in the areas where large arteries branch into smaller ones, generally observed at the base of the brain. Brain aneurysm is also known as cerebral aneurysm or intracranial aneurysm. Aneurysm has the potential to rupture, which causes bleeding in the surrounding sub-arachnoid space, generally resulting in brain damage or stroke. Sometimes, it may lead to even death. Brain aneurysm rarely has any symptoms until the swelling ruptures. However, double vision, localized headache, and cranial nerve palsy are a few symptoms of mass effect of brain aneurysm on adjacent neurological structures. Key causes of brain aneurysm include heredity, aging, atherosclerosis infection, and brain injury.
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/brain-aneurysm-treatment-market.html
Ruptured brain aneurysm is a critical condition and in a few cases, it could be fatal. It is generally diagnosed with the help of magnetic resonance angiography, cerebral angiography, or computed tomography (CT) scan. Brain aneurysm is one of the leading causes of hemorrhagic stroke. According to UCSF Medical Center, approximately 3%–5% of people in the U.S. are affected by brain aneurysm every year. It is mostly prevalent in adults aged 35–60 years. It is also observed to be more prevalent in women than men, with a prevalence ratio of 3:2. According to the Brain Aneurysm Foundation, 1 in 50 people in the U.S. have brain aneurysm. Of these, 40% of the cases are fatal and 60% of the cases suffer from a permanent neurological defect. Every year, 500,000 people die of brain aneurysm across the world. Of these, 50% people are aged 50 years or below. According to a research study conducted by Karger Journal, the rate of mortality after the conservative treatment in the first few months is 50%–60%.
The Federal government spends a mere US$ 0.83 per afflicted person per year on brain aneurysm research. Significant developments over the last few years with volumes of supporting data, rise in the adoption of advanced technologies for the diagnosis and treatment of brain aneurysm, and the genetic factor responsible for occurrence of the disease are factors fueling the brain aneurysm treatment market. On the other hand, high cost of the treatment and unrecognized symptoms of the brain aneurysm are considered to be major restraining factors for the market.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39257
Based on treatment type, the brain aneurysm treatment market has been segmented into medication and surgery. The surgery segment has been sub-segmented into endovascular coiling, flow diverters, surgical clipping, and others. The flow diverters sub-segment has been further divided into silk flow diverters, pipeline embolization devices, and surpass flow diverters. The medication segment has been sub-segmented into analgesics, antiemetics, anti-seizure medications, calcium channel blockers, antacids, and others. Based on type, the brain aneurysm treatment market has been segmented into unruptured aneurysm and ruptured aneurysm. The ruptured aneurysm segment holds a major market share, due to prominent symptoms of ruptured aneurysm and ease of diagnosis. However, advancing technologies in diagnostics and growing initiatives for regular health screenings are anticipated to propel the unruptured aneurysm segment during the forecast period. Based on end-user, the market has been segmented into hospitals, specialty clinics, and others.
Based on geography, the brain aneurysm treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global market during the forecast period, due to availability of advanced screening processes, high health care expenditure, and rise in awareness about the disease in the region. Asia Pacific is expected to be a rapidly growing market for brain aneurysm treatment from 2017 to 2025, due to the rising number of patients, improved diagnosis, and developing health care infrastructure in the region. Some of the key players operating in the brain aneurysm treatment market are Raumedic AG, DePuy Synthes, Integra Life Sciences Corporation, Orsan Medical Technologies, Spiegelberg GmbH, MicroPort Scientific Corporation, Medtronic Plc., and Codman & Shurtleff, Inc.
Request Table of Content of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=39257
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact US:
Transparency Market Research, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 Email: [email protected] Website: https://www.transparencymarketresearch.com
0 notes